SI2791177T1 - Molekule protitelesa, ki vežejo trombin, in uporabe le-teh - Google Patents
Molekule protitelesa, ki vežejo trombin, in uporabe le-teh Download PDFInfo
- Publication number
- SI2791177T1 SI2791177T1 SI201231145T SI201231145T SI2791177T1 SI 2791177 T1 SI2791177 T1 SI 2791177T1 SI 201231145 T SI201231145 T SI 201231145T SI 201231145 T SI201231145 T SI 201231145T SI 2791177 T1 SI2791177 T1 SI 2791177T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibody molecule
- seq
- thrombin
- antibody
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (11)
- Molekule protitelesa, ki vežejo trombin, in uporabe le-teh Patentni zahtevki1. Izolirana molekula protitelesa, ki se specifično veže na območje zunanjega vezavnega mesta 1 trombina, pri čemer molekula protitelesa obsega VH-domeno, ki obsega HCDR1, HCDR2 in HCDR3, ki imajo zaporedja SEQ ID NOs 3, 4 oziroma 5, in VL-domeno, ki obsega LCDR2 in LCDR3, ki imata zaporedji SEQ ID NOs 8 oziroma 9, in LCDR1, ki ima zaporedje SEQ ID NO: 7 ali LCDR1, ki ima zaporedje SEQ ID: 7, v kateri je glikosilacijsko mesto odstranjeno z mutacijo z uvedbo substitucije pri aminokislinskem ostanku, ki ustreza S30 v SEQ ID NO: 6.
- 2. Molekula protitelesa po zahtevku 1, ki zavira trombinsko aktivnost.
- 3. Molekula protitelesa po zahtevku 1 ali zahtevku 2, pri čemer molekula protitelesa obsega VH-domeno, ki ima aminokislinsko zaporedje s SEQ ID NO: 2.
- 4. Molekula protitelesa po katerem koli predhodnem zahtevku, pri čemer molekula protitelesa obsega VL-domeno, ki ima aminokislinsko zaporedje s SEQ ID NO: 6 ali aminokislinsko zaporedje s SEQ ID NO: 6, v katerem je bilo glikosilacijsko mesto odstranjeno z mutacijo z uvedbo substitucije pri aminokislinskem ostanku, ki ustreza S30.
- 5. Molekula protitelesa po katerem koli predhodnem zahtevku, ki je celotno protitelo.
- 6. Molekula protitelesa po zahtevku 5, ki je IgA ali IgG.
- 7. Molekula protitelesa po katerem koli predhodnem zahtevku, ki je monoklonsko protitelo.
- 8. Molekula protitelesa po katerem koli od zahtevkov od 1 do 4, ki je fragment protitelesa.
- 9. Farmacevtski sestavek, ki obsega molekulo protitelesa po katerem koli od zahtevkov od 1 do 8 in farmacevtsko sprejemljivo pomožno snov.
- 10. Molekula protitelesa po katerem koli od zahtevkov od 1 do 8 za uporabo pri postopku zdravljenja človeškega ali živalskega telesa.
- 11. Molekula protitelesa po katerem koli od zahtevkov od 1 do 8 za uporabo pri postopku zdravljenja stanja, ki ga posreduje trombin, in je izbran izmed tromboze in embolije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1121513.4A GB201121513D0 (en) | 2011-12-14 | 2011-12-14 | Thrombin-binding antibody molecules and uses thereof |
| PCT/GB2012/053140 WO2013088164A1 (en) | 2011-12-14 | 2012-12-14 | Thrombin-binding antibody molecules and uses thereof |
| EP12806641.2A EP2791177B1 (en) | 2011-12-14 | 2012-12-14 | Thrombin-binding antibody molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2791177T1 true SI2791177T1 (sl) | 2018-03-30 |
Family
ID=45560465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231145T SI2791177T1 (sl) | 2011-12-14 | 2012-12-14 | Molekule protitelesa, ki vežejo trombin, in uporabe le-teh |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US9518129B2 (sl) |
| EP (2) | EP2791177B1 (sl) |
| JP (2) | JP6216954B2 (sl) |
| KR (1) | KR102114506B1 (sl) |
| CN (2) | CN107936119B (sl) |
| AU (2) | AU2012351858B2 (sl) |
| BR (1) | BR112014014605A2 (sl) |
| CA (1) | CA2856656C (sl) |
| CO (1) | CO7101192A2 (sl) |
| CY (1) | CY1119599T1 (sl) |
| DK (1) | DK2791177T3 (sl) |
| ES (1) | ES2642718T3 (sl) |
| GB (1) | GB201121513D0 (sl) |
| HK (2) | HK1202564A1 (sl) |
| HR (1) | HRP20171775T1 (sl) |
| HU (1) | HUE034793T2 (sl) |
| IL (1) | IL232797B (sl) |
| LT (1) | LT2791177T (sl) |
| ME (1) | ME02901B (sl) |
| MX (1) | MX353281B (sl) |
| MY (1) | MY170980A (sl) |
| NO (1) | NO2791177T3 (sl) |
| PE (2) | PE20190171A1 (sl) |
| PH (1) | PH12014501169A1 (sl) |
| PL (1) | PL2791177T3 (sl) |
| PT (1) | PT2791177T (sl) |
| RS (1) | RS56510B1 (sl) |
| RU (2) | RU2017144629A (sl) |
| SG (1) | SG11201402560WA (sl) |
| SI (1) | SI2791177T1 (sl) |
| UA (1) | UA116531C2 (sl) |
| WO (1) | WO2013088164A1 (sl) |
| ZA (1) | ZA201403836B (sl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
| GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
| GB201310948D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Screening methods |
| GB201310949D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Binding Motif |
| CN107043423B (zh) * | 2016-02-05 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 凝血酶抗体、其抗原结合片段及医药用途 |
| MX2018009264A (es) * | 2016-02-05 | 2018-08-28 | Jiangsu Hengrui Medicine Co | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. |
| WO2018081534A1 (en) * | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
| WO2019030706A1 (en) | 2017-08-10 | 2019-02-14 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY |
| WO2019035055A1 (en) | 2017-08-16 | 2019-02-21 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS |
| WO2020003077A1 (en) * | 2018-06-25 | 2020-01-02 | Janssen Pharmaceutica Nv | Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011297A1 (en) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5240913A (en) | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
| US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
| WO1991017258A1 (en) | 1990-05-10 | 1991-11-14 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5443827A (en) * | 1993-05-03 | 1995-08-22 | President And Fellows Of Harvard College | Fibrin-targeted inhibitors of thrombin |
| EP0738156A1 (en) * | 1993-12-27 | 1996-10-23 | Hamilton Civic Hospitals Research Development, Inc. | Methods and compositions for inhibiting thrombogenesis |
| GB9613718D0 (en) | 1996-06-29 | 1996-08-28 | Thrombosis Res Inst | Thrombin inhibitors |
| US5985833A (en) | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
| WO2001000667A2 (en) | 1999-06-29 | 2001-01-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thrombin peptide from anopheles albimanus salivary gland |
| JP2003526625A (ja) * | 1999-07-23 | 2003-09-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血小板の活性化の調節 |
| KR20030034071A (ko) * | 2000-05-15 | 2003-05-01 | 스미스클라인 비참 코포레이션 | 항혈전제 |
| AU2001286900A1 (en) | 2000-08-31 | 2002-03-13 | Cor Therapeutics, Inc. | Therapeutics and diagnostics based on a novel signal transduction system in platelets |
| AU2002316604A1 (en) * | 2001-07-06 | 2003-01-21 | Oregon Health And Science University | Peptides which modulate blood coagulation and methods of use thereof |
| TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
| EP1928505A4 (en) | 2005-08-26 | 2010-10-27 | Archemix Corp | APTAMERS BINDING TO THROMBIN WITH STRONG AFFINITY |
| CA2680736A1 (en) | 2006-03-15 | 2007-09-20 | Emory University | Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| GB0711779D0 (en) | 2007-06-18 | 2007-07-25 | Univ Singapore | Thrombin inhibitor |
| ES2702365T3 (es) | 2008-06-19 | 2019-02-28 | Prothix Bv | Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos |
| US20110275701A1 (en) * | 2008-09-18 | 2011-11-10 | Archemix Corp. | Anti-thrombin aptamer formulations and methods for use |
| IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses. |
| GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
| US9518128B2 (en) * | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
-
2011
- 2011-12-14 GB GBGB1121513.4A patent/GB201121513D0/en not_active Ceased
-
2012
- 2012-12-14 CN CN201711384542.3A patent/CN107936119B/zh not_active Expired - Fee Related
- 2012-12-14 LT LTEP12806641.2T patent/LT2791177T/lt unknown
- 2012-12-14 SI SI201231145T patent/SI2791177T1/sl unknown
- 2012-12-14 KR KR1020147019168A patent/KR102114506B1/ko active IP Right Grant
- 2012-12-14 UA UAA201406892A patent/UA116531C2/uk unknown
- 2012-12-14 SG SG11201402560WA patent/SG11201402560WA/en unknown
- 2012-12-14 RU RU2017144629A patent/RU2017144629A/ru unknown
- 2012-12-14 RS RS20171073A patent/RS56510B1/sr unknown
- 2012-12-14 AU AU2012351858A patent/AU2012351858B2/en not_active Ceased
- 2012-12-14 MY MYPI2014001764A patent/MY170980A/en unknown
- 2012-12-14 PE PE2018002007A patent/PE20190171A1/es unknown
- 2012-12-14 JP JP2014546649A patent/JP6216954B2/ja not_active Expired - Fee Related
- 2012-12-14 PT PT128066412T patent/PT2791177T/pt unknown
- 2012-12-14 PE PE2014000953A patent/PE20141706A1/es active IP Right Grant
- 2012-12-14 WO PCT/GB2012/053140 patent/WO2013088164A1/en active Application Filing
- 2012-12-14 NO NO12806641A patent/NO2791177T3/no unknown
- 2012-12-14 EP EP12806641.2A patent/EP2791177B1/en active Active
- 2012-12-14 BR BR112014014605A patent/BR112014014605A2/pt not_active Application Discontinuation
- 2012-12-14 US US14/363,514 patent/US9518129B2/en active Active
- 2012-12-14 DK DK12806641.2T patent/DK2791177T3/en active
- 2012-12-14 ME MEP-2017-243A patent/ME02901B/me unknown
- 2012-12-14 CA CA2856656A patent/CA2856656C/en active Active
- 2012-12-14 RU RU2014124985A patent/RU2642276C2/ru active
- 2012-12-14 MX MX2014007170A patent/MX353281B/es active IP Right Grant
- 2012-12-14 CN CN201280061294.8A patent/CN104053673B/zh not_active Expired - Fee Related
- 2012-12-14 EP EP17177235.3A patent/EP3275903A1/en not_active Withdrawn
- 2012-12-14 HU HUE12806641A patent/HUE034793T2/en unknown
- 2012-12-14 ES ES12806641.2T patent/ES2642718T3/es active Active
- 2012-12-14 PL PL12806641T patent/PL2791177T3/pl unknown
-
2014
- 2014-05-26 PH PH12014501169A patent/PH12014501169A1/en unknown
- 2014-05-26 ZA ZA2014/03836A patent/ZA201403836B/en unknown
- 2014-05-26 IL IL232797A patent/IL232797B/en active IP Right Grant
- 2014-07-11 CO CO14150372A patent/CO7101192A2/es unknown
-
2015
- 2015-03-27 HK HK15103146.0A patent/HK1202564A1/xx not_active IP Right Cessation
-
2016
- 2016-11-10 US US15/348,250 patent/US9988463B2/en active Active
-
2017
- 2017-08-30 JP JP2017165700A patent/JP6705785B2/ja not_active Expired - Fee Related
- 2017-11-14 CY CY20171101189T patent/CY1119599T1/el unknown
- 2017-11-16 HR HRP20171775TT patent/HRP20171775T1/hr unknown
- 2017-12-01 AU AU2017268655A patent/AU2017268655B2/en not_active Ceased
-
2018
- 2018-05-08 HK HK18105913.3A patent/HK1246326A1/zh unknown
- 2018-05-10 US US15/976,512 patent/US10287363B2/en not_active Expired - Fee Related
-
2019
- 2019-03-25 US US16/363,396 patent/US20190276558A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/344,577 patent/US20210371543A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2791177T1 (sl) | Molekule protitelesa, ki vežejo trombin, in uporabe le-teh | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| SI3042917T1 (sl) | Protitelesa proti n3pglu amiloid beta peptidu in njihova uporaba | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| RS53157B (en) | SCLEROSTINE ANTIBODIES | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2013121353A5 (sl) | ||
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| PE20081503A1 (es) | Miembros de union para il-6 | |
| JP2015514110A5 (sl) | ||
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| NZ603529A (en) | Antibodies to human gdf8 | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| RU2017128882A (ru) | Антитела к биотину и способы их применения | |
| EP2604280A3 (en) | Compositions and methods for inhibiting PDGFRBETA and VEGF-A | |
| JP2015503909A5 (sl) | ||
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| NZ714313A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| JP2011502137A5 (sl) | ||
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| JP2016538876A5 (sl) |